Novartis Archives

News and Trends 4 Dec 2015

Delenex Therapeutics, the Swiss Biotech developing new types of Therapeutic Antibodies

This week we leave the old city of Oxford and travel South East across the channel, through France and arrive at our destination, Zurich, Switzerland. This wonderful city is famous for its many churches (including the Minster), the largest church clock in Europe, found on St Peter’s and is the home of many celebrities including […]

December 4, 2015 - 2 minutesmins - By Philip Hemme

biosimilar war neulasta herceptin avastin rituxan1

News and Trends 25 Nov 2015

Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War!

Novartis is hitting back in the Biosimilar battleground: now Neulasta, the white blood cell booster for Cancer, is the latest of Amgen’s victims… Neulasta (pegfilgrastim) has been submitted through Novartis’ subsidiary, Sandoz. As a recombinant human granulocyte colony-stimulating factor (G-CSF), pegfilgrastim looks to stimulate the immune system and boost the white cell count. Neulasta is […]

November 25, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 6 Nov 2015

Cellectis’ Miraculous Saving of a Baby Girl. What’s the impact on the CAR-T field?

About 30%. That’s how Cellectis‘ NASDAQ stock price has jumped between the 4th and the 5th of November. But why? Basically, because of the first human success of their allogeneic CAR-T therapy! The Great Ormond Street Hospital (UK) treated a young patient with refractory relapsed Acute Lymphoblastic Leukemia (ALL) with Cellectis’ allogeneic UCART19 product candidate in June. To […]

November 6, 2015 - 2 minutesmins - By Jerome Topsent

News and Trends 29 Oct 2015

Naughty Novartis…US Department of Justice Fines them $390M – Again!

Being a multi-billion international Pharmaceutical giant does not protect you from the Law…and in my best American accent “Justice WILL be served” (and bang! goes the gavel). Novartis gets called out on their dodgy sales boosting techniques again down the US Federal court. Novartis has been caught out serving Pharmacists and Doctors under the table […]

October 29, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 23 Oct 2015

Novartis Monopolises Immuno-Oncology: Three More Biotechs taken Under its Wing

Novartis, the Swiss Biotech giant, has once again broadened its Immuno-oncology portfolio with the acquisition of US Admune Therapeutics (MA) and forming marketing, commercialization and development partnerships with California’s Xoma and Palobiopharma in Barcelona (Spain). Novartis is a Basel giant in the biotech industry, with their research development programs spanning a broad range of fields […]

October 23, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 15 Oct 2015

Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology

Ablynx – the Belgian nanobody biotech (which uses monoclonal antibodies of Alpacas), has now achieved it’s first pre-clinical milestone in its immuno-oncology partnership with MSD (Merck & Co). Now Ablynx has achieved proof of concept for one of the 17 Nanobodies being studied. Ablynx has therefore received the first €3.5M in milestone payments from MSD […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

No, Novartis and Roche won’t merge (yet)!

Novartis already owns 33% of Roche, but even if both companies are headquartered in the same city of Basel (Switzerland), they still have no plans to merge. Joerg Reinhardt, The Chairman of Novartis – the second biggest Pharma company worldwide by market cap (€212Bn – J&J: €231Bn), was asked about it on the Swiss TV Bilanz […]

October 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Oct 2015

Why can’t Novartis Commit to the Israeli Biotech Scene?

Novartis, the Swiss Acquisition-Giant from Basel, has once again taken bought a small chunk of shares from the Israel biotech scene for only $15M (2.5%), instead of making a final solid purchase. The Jerusalem biotech Gamida Cell, which has a stem-cell therapies for hematological diseases (leukemia and various types of anemia), was underwhelmed a second […]

October 13, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 5 Oct 2015

Manfred Horst on MSD, Biosimilars, KEYTRUDA and his Company’s rich history

Manfred Horst is a Director Business Development Europe and working from an office at MSD France, the French affiliate of MSD which has its HQ in New Jersey (and is known as Merck & Co. in the US). MSD is one of the biggest pharmaceutical companies in the world with a 2014 revenue of €37.4Bn and €6.4Bn […]

October 5, 2015 - 6 minutesmins - By Julie Lellouche

News and Trends 29 Sep 2015

Could an Alpaca’s monoclonal antibodies be used to treat an ultra-rare blood disease?

Ablynx‘s Nanobody platform has used the smaller than human monoclonal antibodies from an alpaca to develop the phase III Orphan designated drug Caplacizumab. A phase III study ‘Hercules’ is now pioneering Caplacizumab as the first ever anti-Von Willebrand factor (vWF) nanobody for treating an ultra-rare blood clotting disorder. Caplacizumab is a pioneering monoclonal antibody (mAb) […]

September 29, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 10 Sep 2015

Debiopharm teams up with Solid Biosciences to treat DMD

The Debiopharm Group, headquartered in Lausanne (Switzerland) has announced its Alisporovir brand will under-go preclinical trials to treat Duchenne Muscular Dystrophy (DMD) in collaboration with Solid Biosciences, a Cambridge (MA) biotech dedicated to research of DMD. The Debiopharm Group has been around for over 40 years, with 4 international subsidiary companies within the Swiss-based group. […]

September 10, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 8 Sep 2015

The First Biosimilar reached the US market… and it’s from Novartis

Biosimilar or copies of biological drugs are arriving on the market. After Europe, US gets its first Biosimilar too. The drug is produced by Novartis generic subsidiary, Sandoz and it will compete with Amgen‘s blockbuster drug Neupogen. When a drug generates $1.2Bn of annual revenues and its patent has expired, which company on earth wouldn’t be […]

September 8, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us